| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2013.02.027 |
| P698 | PubMed publication ID | 23541564 |
| P50 | author | Gunter von Minckwitz | Q11163000 |
| Sibylle Loibl | Q38291860 | ||
| Holger Eidtmann | Q38292590 | ||
| Michael Untch | Q38292680 | ||
| Valentina Nekljudova | Q38292757 | ||
| Jens Huober | Q38293194 | ||
| Sherko Kümmel | Q38295911 | ||
| Peter A. Fasching | Q64005064 | ||
| P2093 | author name string | Christian Jackisch | |
| Hans Tesch | |||
| Jens-Uwe Blohmer | |||
| Serban Dan Costa | |||
| Bernd Gerber | |||
| Mahdi Rezai | |||
| Christine Mau | |||
| Petra Krabisch | |||
| Claus Hanusch | |||
| Jörn Hilfrich | |||
| Kathrin Schwedler | |||
| Kornelia Kittel | |||
| Fariba Khandan | |||
| Cornelia Höß | |||
| P433 | issue | 10 | |
| P921 | main subject | bevacizumab | Q413299 |
| paclitaxel | Q423762 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 2284-2293 | |
| P577 | publication date | 2013-03-27 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). | |
| P478 | volume | 49 |
| Q26999473 | Anti-vascular endothelial growth factor therapy in breast cancer |
| Q27332151 | Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer |
| Q56968709 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study |
| Q34232366 | Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis |
| Q37690076 | Clinical development of mTOR inhibitors in breast cancer |
| Q47260496 | Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years |
| Q64982162 | Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. |
| Q48252794 | Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. |
| Q34673530 | Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway |
| Q35191651 | Everolimus in acute kidney injury in a patient with breast cancer: a case report |
| Q46721561 | Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study |
| Q53618240 | Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. |
| Q38682028 | Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis |
| Q34547982 | Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials |
| Q53752984 | Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). |
| Q33683126 | Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. |
| Q26771394 | PI3K/Akt/mTOR inhibitors in breast cancer |
| Q42934611 | Pathway-oriented concepts in adjuvant and neoadjuvant breast cancer therapy. |
| Q35689902 | Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study |
| Q38949880 | Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). |
| Q38312035 | Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. |
| Q53809725 | Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. |
| Q52871581 | Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. |
| Q35232357 | Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis |
| Q38494344 | Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. |
| Q38841039 | Safety of mTOR inhibitors in breast cancer |
| Q26777736 | Targeted Therapies in Triple-Negative Breast Cancer |
| Q37190825 | Targeted therapy for breast cancer prevention |
| Q39390640 | Targeting the mTOR pathway in breast cancer |
| Q46909057 | Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials |
| Q27009257 | Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes |
Search more.